Ophthalmology treatments and biotech updates from Eyepoint Pharmaceuticals

  • Mykhailo Ihnatenko
  • 12.11.2026
Eyepoint Pharmaceuticals outlines Q3 2026 financial update alongside clinical progress
Eyepoint Pharmaceuticals announced its financial results for the third quarter of 2026, along with an update on its clinical development program and business priorities. The statement provides a ...
  • Pavlo Kot
  • 19.10.2026
Eyepoint Pharmaceuticals announces topline results from second pivotal Phase 3 LUCIA trial
Eyepoint Pharmaceuticals announced topline results from LUCIA, its second pivotal Phase 3 clinical trial for DURAVYU for the treatment of wet age-related macular degeneration (AMD). The company ...
  • Yaroslav Dmytrenko
  • 28.09.2026
Eyepoint Pharmaceuticals presents updated DURAVYU data with new real world insights
Eyepoint Pharmaceuticals introduced new and incremental results from four presentations at RetinaSociety2026, deepening the understanding of its DURAVYU treatment. The company unveiled additional ...
  • Alena Volkova
  • 03.09.2026
Eyepoint Pharmaceuticals LUGANO Phase 3 results point to new treatment options for wet AMD
Eyepoint Pharmaceuticals has released the results of its LUGANO Phase 3 clinical trial, bringing renewed attention to treatment prospects for patients suffering from wet age-related macular ...
  • Pavlo Kot
  • 02.09.2026
Eyepoint Pharmaceuticals sends team to New York to engage with industry leaders
Eyepoint Pharmaceuticals is sending its team to New York City to participate in several investor conferences. The company aims to connect with industry leaders and provide updates on its ...
  • Ashutosh Sureka
  • 26.08.2026
Eyepoint Pharmaceuticals topline Lugano trial results spark momentum for sustained release TKI in wet AMD
Eyepoint Pharmaceuticals revealed topline results from its Lugano trial, showing promising efficacy for sustained release tyrosine kinase inhibitors (TKIs) in the treatment of wet age-related ...
  • Elena Nikulina
  • 17.08.2026
Eyepoint Pharmaceuticals announces pivotal data readout for DURAVYU in wet AMD
Eyepoint Pharmaceuticals has announced topline results from its LUGANO trial, the first of two pivotal Phase 3 studies evaluating DURAVYU for the treatment of wet age-related macular degeneration ...
  • Yulia Slavina
  • 05.08.2026
Eyepoint Pharmaceuticals posts Q2 2026 results and details recent corporate moves
Eyepoint Pharmaceuticals released its financial results for the second quarter of 2026, revealing key figures and strategic corporate developments. The pharmaceutical company used this update to ...
  • Dmytro Kharkov
  • 30.07.2026
Topline DURAVYU Phase 3 data for DME expected in late 2027 as Eyepoint Pharmaceuticals advances studies
Eyepoint Pharmaceuticals has announced the completion of patient enrollment in both pivotal Phase 3 clinical trials of its investigational therapy DURAVYU for diabetic macular edema (DME). The ...
  • Anastasiia Chabaniuk
  • 13.07.2026
Eyepoint Pharmaceuticals appoints Tarek S Hassan as chief strategic science officer for wet AMD push
Eyepoint Pharmaceuticals has named Tarek S Hassan, M.D., as its new chief strategic science officer, bringing more than 35 years of ophthalmology experience to the executive team. The ...
  • Mikhail Vnuchkov
  • 06.07.2026
Eyepoint Pharmaceuticals aims to foster new approaches in retina care at Montreal ASRS gathering
Eyepoint Pharmaceuticals is set to participate in the ASRS 44th Annual Meeting in Montreal, focusing on engaging with the retina community to explore innovative strategies for advancing treatments ...
  • Hanna Syniavska
  • 23.06.2026
Eyepoint Pharmaceuticals urges vigilance as wet AMD symptoms develop rapidly
Eyepoint Pharmaceuticals urges individuals to monitor for rapid-onset symptoms of wet age-related macular degeneration (AMD) and prioritize regular eye examinations. The company is actively ...
  • Mikhail Vnuchkov
  • 10.06.2026
Eyepoint Pharmaceuticals brings latest advances in retinal science to CTS Retina 2026
Eyepoint Pharmaceuticals announced its participation in the upcoming CTS Retina 2026 conference, set to take place in Las Vegas. On June 13th, Dr. Ashkan M. Abbey and Dr. Tarek S. Hassan are ...
  • Andrey Mastykin
  • 04.06.2026
Eyepoint Pharmaceuticals advances new therapies for serious retinal diseases in June campaign
Eyepoint Pharmaceuticals is advancing potential therapies targeting serious retinal diseases such as diabetic macular edema (DME) as part of its observance of Mens Health Month in June. The ...
  • Parshwa Turakhiya
  • 02.06.2026
Eyepoint Pharmaceuticals to participate in Jefferies Global Healthcare event webcast
Eyepoint Pharmaceuticals announced that members of its management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York tomorrow. The company ...
  • Igor Krasulya
  • 29.05.2026
Eyepoint Pharmaceuticals CEO featured for advances in OCT retina imaging tool
Eyepoint Pharmaceuticals president and CEO Jay S. Duker, M.D., has been recognized in Retina Today’s ‘Then and Now’ spotlight for his perspective on the progress of optical coherence ...
  • Oleg Tkachenko
  • 26.05.2026
Eyepoint Pharmaceuticals drives research to develop treatments for serious retinal conditions
Eyepoint Pharmaceuticals is intensifying efforts to translate scientific discovery into tangible therapies for patients with severe retinal diseases. The company is spotlighting its Northbridge, ...